… or weight > 120 kg due to limited clinical data in morbidly obese patients. The aim of …
meta-analysis was to compare DOACs with warfarin in morbidly obese patients with atrial fibrillation …

… direct oral anticoagulants (DOACs). This meta-analysis aimed to explore if there is an “obesity …
In the present meta-analysis, compared with normal weight, underweight was associated …

… We conducted a systematic review and meta-analysis on … of direct oral anticoagulants (DOAC)
compared to vitamin K antagonists (VKA) in morbidly obese patients with atrial fibrillation (…

… Our meta-analysis demonstrated that DOACs are effective and safe with statistical superiority
when compared with warfarin in morbidly obese patients. Large-scale randomized clinical …

… meta-analysis comprising real-world observational data concludes that the use of DOAC
analogs in morbidly obese patients (bodyweight of > 120 kg or BMI … 2 ) with atrial fibrillation and …

… The aim of this study is to compare the effectiveness and safety of direct oral … metaanalysis
is to compare the effectiveness and safety of DOACs in obese patients with atrial fibrillation …

… for the treatment of acute VTE in patients with morbid obesity compared to those with non-…
This is also consistent with the obesity paradox described in atrial fibrillation cohorts treated …

… our meta-analysis did not show any significant difference between all body mass index (BMI) …
the safety and effectiveness of direct oral anticoagulants (DOACs) in obese adults with AF. …

… metaanalysis of the studies that directly compared DOACs with VKAs or LMWH in morbidly
obese patients… trials in patients with acute VTE and non-valvular atrial fibrillation (NVAF) have …

… at the extremes of body weight, as this meta-analysis has highlighted the at least preserved
effectiveness and safety profile of NOACs compared to VKAs in (morbidly) obese AF patients …